



COVID-19 RESPONSE MECHANISM

UNITE^{TO} FIGHT

C19RM Monthly Update to the Board

Report for March 2022

Publication Date: 7th April 2022

Geneva, Switzerland

Executive Summary for March Report – Data Only

1 Development of C19RM Monthly Reporting

2 Update on COVID-19 Epidemiological Situation

3 C19RM 2021 Awards

4 Finance Update

5 Health Products Update

1 Development of C19RM Reporting.
This report includes updates on key data points for awards, financial information and health products. Future reports will adopt a differentiated approach to ensure delivery of monthly reports to the Board that present updates on key data points, while more detailed analysis and reports will be provided when Spot Checks and Pulse Checks data is available. For previous versions of Board reports visit [this page](#).

2 Update on COVID-19 Epidemiological Situation.
High Impact Asia remains the region with the highest confirmed cases. Increase in new cases have also been recorded in Southeast Asia. Whereas disruptions have considerably hindered progress in programs for the three diseases, program adaptations have started to show signs of recovery and resilience. We will still need to do more to catch up on lost ground due to COVID-19.

3 C19RM 2021 Awards.
As of 31 March 2022, C19RM has awarded or recommended for Board approval US\$3,369 million to 124 applicants, for a portfolio average of 26.2% of the 2020-2022 allocation with the following breakdown: 75% to reinforce national COVID-19 responses, 14% for urgent improvement to health and community systems, and 11% for HIV, TB and malaria mitigation.

4 Finance Update.
C19RM 2020 in-country implementation and utilization is at 56% (US\$ 550 million) and on target to reach 63%-70% with expenditures currently under validation in the grant closures and forthcoming expenditure reports. C19RM 2021 - disbursements (31 Mar 2022) accelerated to 80% of Year 1 budget despite implementation starting late in 2021, following completion of award stage.

5 Health Products Update.
Approximately 67% of awards are allocated to health products. As of 31 March, 52% of total C19RM 2021 procurement planned through the Pooled Procurement Mechanism (PPM) is confirmed as purchase order (PO) or in process of approval (US\$700M / US\$1,345M). Of the total of US\$3,369 million awarded by 31 March:

- [Diagnostics](#) remain a priority, representing around US\$782 million or 23% of awarded C19RM 2021 funds steady progress on the conversion of approved budgets for diagnostics into orders.
- US\$543 million for [Oxygen](#) and clinical care-related products representing 16.1% of total awards. Out of the US\$184 million invested in [non-oxygen therapeutics](#), and tenders are ongoing with manufacturers to secure supply capacity for LMIC served by the Global Fund, with US\$50M of set aside Centrally Managed Limited Investments to ensure early access to selected novel therapeutics products.
- US\$491 million for Personal Protective Equipment ([PPE](#)) with further 13% price reductions in Q1 2022 with overall product price reductions of 60% since beginning of peak demand in early 2020.



1

Development of C19RM Reporting



Development of C19RM Monthly Reporting

In last month's report, we covered COVID-19 program disruption, award and pipeline updates, health products overview and key areas of investment. We will continue to update these sections on subsequent reports and provide additional analysis on emerging themes. Greater details on these core sections will be included as relevant data becomes available.

Last Report

Last Report

- Update on the COVID-19 Epidemiological Situation.
- **C19RM 2021 Awards**
- **Finance Update** with estimated expenditure until June 2021.
- **Health Products Overview.**
- **Delivering on C19RM** includes examples the three key areas of investment:
 - **Reinforcing COVID-19 Response**, including strengthening diagnostics, therapeutics and PPE.
 - **Mitigating the Impact on HIV, TB and Malaria**, including examples of programs that have demonstrated resilience and adaptation.
- **Risk Assurance, Monitoring and Oversight framework** with further details on Spot Checks and Pulse Checks and lessons learnt. LFA C19RM Assurance is also included.

This Report

Objectives of Current Report: Provide updates on key data points.

- Update on the COVID-19 Epidemiological Situation.
- **C19RM 2021 Awards**
- **Finance Update**
- **Updates on Health Products Pipeline**
 - Overview
 - Diagnostics
 - Oxygen
 - Therapeutics
 - ICP/PPE

Subsequent Reports...

Future reports will adopt a differentiated approach.

Data reports are providing the Board with consistent monthly updates on key selected data points updates from financial and programmatic performance. More detailed reports including analysis will be provided on a quarterly basis as data from Spot Checks and Pulse Checks becomes available.

- **Monthly Reports (Key data)**, including updates on awards, progress in absorption / funds utilization and procurement pipeline.
- **Quarterly Reports:** focusing on programmatic data / results, findings and insights from Spot Checks and Pulse Checks, lessons learned, strategic actions taken to address challenges and bottlenecks and key issues and messages from operationalization of C19RM.



2


Update on COVID-19 Epidemiological Situation



COVID-19 Burden in the Regions We Support

High Impact Asia remains the region with the highest confirmed cases. Whereas disruptions have considerably hindered progress in programs for the three diseases, program adaptations have started to show signs of recovery and resilience. We will still need to do more to catch-up on lost ground due to COVID-19.

Number of New COVID-19 Cases per Global Fund Region



True infections far outnumber confirmed cases in many countries. See <https://ourworldindata.org/covid-models>

***High Impact Africa 2:** South Africa, Ethiopia, Kenya, Zambia, Mozambique, Zimbabwe, Uganda, Zanzibar
****MENA:** Morocco, Tunisia, Egypt, Algeria, Mauritania, Sudan.

SUMMARY

- According to WHO, as of 1 April 2022, there have been 486,761,597 confirmed cases of COVID-19, including 6,142,735 deaths reported to WHO worldwide. Confirmed cases in the Global Fund portfolio are 142,700,848 while deaths are 2,133,716. **High Impact Asia has 69,553,098 confirmed cases, an increase of more than 11 million in two months.** New cases have also been recorded in **Southeast Asia leading to a total of 27,748,716 million, with an increase of 122% in 2 months.**
- Confirmed cases in Latin America and Caribbean remain at over 17 million while those in *High Impact Africa 2 continue to rise to over 5 million while the **MENA region is at over 3 million. **7 Global Fund implementing countries are also among the top 25 countries in the world with the highest cumulative cases.** These include India, Vietnam, Iran, Colombia, Indonesia, Ukraine, Malaysia.



C19RM 2021: Awards



C19RM 2021 Awards: Highlights

C19RM 2021 Fast-track requests Awarded

- The Global Fund has awarded US\$696 million to 44 applicants via Fast-track. Applicants to Fast-track have requested an average of 7.3% of their 2020-2022 allocation.
- Notification Letters with confirmation of awards are sent to applicants in an average of 7.8 business days.
- In March, 15 additional funding requests have been approved for US\$136 million, including US\$54 million for Diagnostics and US\$35 million for Oxygen.


C19RM 2021 Full Funding Requests Awarded

- US\$2,674 million awarded to 124 applicants, including funding recommended for Board approval, for a portfolio average of 20.8% of 2020-2022 allocation (excluding previously approved Fast-track applications).
- An Unfunded Demand of US\$1,043 million registered from 73 applicants.

C19RM 2021 Awarded by Priority Area, WHO pillar and ACT Accelerator pillar

- **C19RM Board Priority Areas:** US\$3,369 million have been awarded or recommended for Board approval with the following breakdown: 75% to reinforce national COVID-19 responses, 14% for urgent improvement to health and community systems, and 11% for HIV, TB and malaria mitigation.
- **WHO Pillars:** C19RM awards are primarily directed towards **Pillar 5: National laboratories (27%)**, **Pillar 6: Infection prevention and control (23%)** and **Pillar 7: Case management (Th%).**e remaining investments are mostly awarded into **Pillar 9: Maintaining essential health services and systems (11%)**.
- **ACT-A Pillars:** 85% of the \$3,369 million C19RM awards is directed towards **ACT-A Gap Filling Activities**.

C19RM 2021 Status of Awards Submissions and Pipeline



US\$3,369 million (92%) of C19RM 2021 funding is awarded or recommended for Board Approval to 124 applicants (either Fast-track or Full Funding) for a portfolio average of 26.2% of 2020-2022 allocation.


Full Funding requests: US\$2,674 million was awarded or recommended for Board approval to 124 applicants.

Fast-track requests: US\$696 million was awarded to 44 applicants.

Including Unfunded Demand of US\$1,043 million (registered from 73 applicants), the total of C19RM Investment Committee decisions is US\$4,954 million. This includes US\$542 million of activities not approved.

Demand pipeline: 2% or US\$76 million has been submitted or under review for potential C19RM 2021 funding. **US\$61 million** is projected for submission or resubmission.

C19RM 2021 Awarded & Requested Amounts




All values are in US\$ million and rounded. Incomplete submissions are also reported. The full submitted amount is considered.

*Pipeline includes: submissions under review, in screening, projected resubmissions and remaining eligible applicants.

- Available funds have increased to **US\$3,673 million** with a new pledge from the **UK (US\$73.5 million)** and additional pledges from **Canada (US\$26 million)** and **Germany (US\$193 million)**. The **Fast-track ceiling** has also been increased by the AFC to **US\$1,168 million**.
- A total of **21 additional funding** requests have been submitted, of which **15** have been awarded, **5 are under review (US\$62 million)**, including US\$6m Above Base) and **1 request is pending clarifications (US\$14 million)**. **US\$61 million** of requests is still **projected** to be submitted.

C19RM 2021 Overall Award: Submission Drill Down




US\$3,369 million (92%) of C19RM 2021 funding is awarded or recommended for Board approval.


Demand pipeline is robust in funding requests received/in process showing demand exceeds supply of available funds:

- Country demand is high with the **majority of applicants requesting 30% of 2020-2022 allocation or more.**
- **Unfunded demand of US\$1,043 million** is registered from **73 applicants.**

Awarding of C19RM 2021



Awards/Submissions by Region



Award (Fast track)
 Award (Full Review)
 Submitted Fast track
 Submitted Full review
 Projected submissions/resubmissions

All values are in US\$ million and rounded.

For values in screening and under review only complete submissions are considered.


Values under Full Funding request awards also include values recommended for board approval

C19RM 2021 Fast-track Drill Down




- **US\$696 million is awarded** to 44 applicants via Fast-track (with an average of 7.3% of applicants 2020-2022 allocation). This represents 60%* of the total Fast-track mechanism.
- An additional US\$76 million or 6%* of the Fast-track mechanism is currently in screening/review.
- In total **60 Fast-track requests have been received, including 4 to be resubmitted due to incomplete documentation or withdrawn.**

Fast-track awards



Award by region



All values are in US\$ million and rounded.
For values in screening and under review only complete submissions are considered.

Already awarded
 FT submitted
 Remaining

**The Fast-track ceiling has been increased by AFC on 30 March 2022.*


C19RM 2021 Award by Priority Area



Award by priority area: Investments are mainly directed towards reinforcing COVID-19 national response.

Out of the Full Funding requests **awarded or recommended for Board approval**, we continue to see prioritization of reinforcing the COVID-19 national response.

C19RM 2021 Awards by Priority Area




All values in the charts are in US\$ million and rounded.

Program management costs are included in Reinforce. Recent awards values may be adjusted slightly once Detailed Budgets are finalized.


Values above include Fast-track awards and Full Funding requests awarded and/ or recommended for Board approval

C19RM 2021 Investments in Mitigation



- Of the US\$3,369 million awarded (including recommendations for Board approval), **US\$367 million (11%) is invested in mitigating the impact of COVID-19 on HIV, TB and malaria programs.**
- Investments in mitigating the impact of COVID-19 are primarily covered within the core HIV, TB, malaria grants (2020-2022 allocation); Malaria grants (2020-2022 allocation) incorporated a significant amount of PPE needs for mass campaigns and community activities.

C19RM 2021 Awards in Mitigation




C19RM 2021 Award by Priority Area




Award by priority area: Fast-track investments are mainly directed towards reinforcing COVID-19 national response.

Full Funding investments show a **more balanced picture across the three priority areas.**

C19RM 2021 Fast-track Awards by Priority Area



C19RM 2021 Full Funding Awards by Priority Area



All values in the charts are in US\$ million and rounded.

Program management costs are included in Reinforce.

Recent awards values may be adjusted slightly once Detailed Budgets are finalized.

Values above include Fast-track awards and Full Funding requests awarded and/ or recommended for Board approval


C19RM 2021 Award by Health Products



Health product investments are more balanced across key health products.

Approximately **65% of awards to date** are expected to use PPM/wambo as the procurement channel.

C19RM 2021 Awards by Type



All values in the charts are in US\$ million and rounded. Recent awards values may be adjusted slightly once HPMTs are finalized. Note that these values exclude C19RM 2020 carryover amounts, which are removed, if found in 2021 HPMTs. Values above include Fast-track awards, Full Funding requests awarded and/ or recommended for board approval. Differences in values between Global Fund defined health products are accounted for by a more limited set of products that are included under these categories.

*Other Health Products include: non-PPE disinfectants, Waste management and genomic sequencing.

**Other non-Health Product investments include: most activities within "Mitigating COVID-19 impact on HIV, TB and malaria" and "Urgent improvements to health and community systems" as well as non-health product awards within "Reinforce COVID-19 national response".


C19RM 2021 Award by WHO Pillars



C19RM investments are primarily directed towards **Pillar 5: National laboratories (27%)**, **Pillar 6: Infection prevention and control (23%)** and **Pillar 7: Case management (25%)**

The remaining investments are mostly invested into **Pillar 9: Maintaining essential health services and systems (11%)**.

C19RM 2021 Awards by WHO Pillar



All values in the charts are in US\$ million and rounded. Recent awards values may be adjusted slightly once Detailed Budgets are finalized.

Values above include Fast-track awards, Full Funding requests awarded and/ or recommended for board approval.


C19RM 2021 Award by ACT-A Pillars



85% of US\$3,369 million of C19RM 2021 investments are directed towards ACT-A Gap Filling Activities given most awards to date are via Fast-track and Full Funding request prioritize reinforcing the COVID-19 response. These investments are split across the **Diagnostics Pillar (\$924 million or 27%)**, the **Therapeutics Pillar (\$834 million or 25%)**, and **Health Systems and Response Connector (\$1,109 million or 33%)**.

The share of complementary activities has increased with Full Funding requests forming the majority of awards.

C19RM 2021 Awards by ACT-A Pillar



All values in the charts are in USD million and rounded.


Recent awards values may be adjusted slightly once Detailed Budgets are finalized.

Values above include Fast-track awards, Full Funding requests awarded and/or recommended for board approval.




4

Finance Update




C19RM 2020 - Current in-country utilization of 56% based on validated expenditures, on-track to reach the expected target of 63% - 70% once expenditure is validated. This includes completion of the closure process.



- **C19RM 2020 in-country utilization is 56%** and on target to reach the expected utilization range of **63% - 70%** (estimate reported in AFC 17) with expenditures currently under validation in the grant closures & forthcoming expenditure reports.
- Unused C19RM 2020 allocation is not considered as expired as these are transferred to C19RM 2021 with a use by date of 31 December 2023.

C19RM 2021 - Disbursements as of 31st March 2022 accelerated to 80% of Year 1 budget despite implementation starting late in 2021, following completion of award stage.



- 93% of awards are integrated into grants
- > 100% of Year 1 budget has been committed
- 53% of Year 1 budget (US\$ 592m) disbursed at 31 December 2021, despite that implementation started later in 2021
- **Post December 2021, total cumulative disbursements accelerated to reach US\$ 900m, representing 80% of Year 1 budget**



5

Health Products Update




Countries need support to convert approved funds into products to accelerate delivery and implementation.

	Health Product Demand	Health Product Sourcing and Supply
General	<ul style="list-style-type: none"> 67% of C19RM 2021 awards are allocated to health products. As of 31 March, 52% of total C19RM 2021 procurement planned through the Pooled Procurement Mechanism (PPM) is confirmed as purchase order (PO) or in process of approval (\$700M / \$1,345). To accelerate implementation, it is necessary to further intensify support to PRs to convert approved funding into planned deliveries or re-programming for 2022-2023. 	<ul style="list-style-type: none"> The global challenges of scarcity of air and sea freight capacity for some routes remains a challenge, as well as port congestion and sporadic short-notice COVID-19 control measures at origin and/or destination. Closely following-up on national importation clearance bottlenecks and some country level supply chain congestion to enable smooth flow of products as some shipments can wait several weeks for such clearances.
Diagnostics	<ul style="list-style-type: none"> Diagnostics represent around 23% of awarded C19RM 2021 funds (US\$782 million) equivalent to about 165-200 million tests There is steady progress on the conversion of approved budgets for diagnostics into orders. Price reductions and also availability of other lower priced Ag-RDTs will allow more tests to be procured including for self-testing. Cross-secretariat and partner efforts continue through Project Stellar to support countries reaching recommended testing levels. 	<ul style="list-style-type: none"> Increasing supplier base of QA-approved Ag RDTs including for self-testing that can support countries to accelerate their testing coverage through lower pricing <ul style="list-style-type: none"> Lowest prices are less than \$1 per test Self-tests available with the manufacturer lead time of 1 to 4 weeks and prices ranging from around \$1.00 - 5.00 per test Some tests now have a longer shelf life of up to 24 months Average weighted pricing in \$1-2 range achievable in H1 2022 with a combination of supply & demand interventions
Infection Prevention and Control	<ul style="list-style-type: none"> Personal protective equipment (PPE): represents around 14.6% of total awarded C19RM 2021 funds. A large proportion of approved budgets for procurement through PPM remains to be placed as requisitions by PRs . 	<ul style="list-style-type: none"> Further 13% price reductions in Q1 2022 with overall product price reductions of 60% since beginning of peak demand in early 2020 High product availability despite manufacturing capacity reductions due to decreasing global demand through 2021 (including in high-income countries) Price increases forecasted for Q2 2022 Energy price increases may begin to be reflected in PPE pricing going forward
Case Management	<p>Oxygen:</p> <ul style="list-style-type: none"> 16.1% of awarded C19RM 2021 funds being allocated for oxygen interventions. Utilization of funds is slow due to the complexity associated with Pressure Swing Adsorption (PSA) plants. <p>Therapeutics:</p> <ul style="list-style-type: none"> Gearing up for new product introduction and demand generation for antivirals including through test-and-treat 	<p>Oxygen</p> <ul style="list-style-type: none"> PSA plant solutions are available through PPM/wambo.org with suppliers' capacity mapped to potential demand. O2 technical working group supporting countries with the procurement and implementation. <p>Therapeutics</p> <ul style="list-style-type: none"> Tenders and negotiations ongoing with manufacturers to secure supply capacity for LMIC served by the Global Fund. Centrally-managed limited investments set aside US\$50M to ensure early access to selected novel therapeutic products.


Orders for US\$749 million of COVID-19-related health products have been placed through the PPM/wambo.org since 2020, with US\$441 million delivered.

- US\$2.7 billion has been awarded since 2020 for the procurement of COVID-19 health products
 - including through C19RM 2021 – Dx: US\$782 million; PPE: US\$491 million; O2: US\$543 million.
- US\$263 million products delivered through PPM with C19RM 2020 funds
- US\$178 million delivered through PPM with C19RM 2021 funds and another US\$307 million products are on their way

Cumulative PPM Procurement Pipeline**



Cumulative PPM Deliveries by Month****




* Inclusive of the funds for getting products to country
 ** Based on Procurement Service Agent data as of 28 March 2022
 *** Production includes process through to importation clearance and pick-up for transfer to flight/vessel
 **** Dollar value of deliveries by month may change slightly over time due to potential reporting lags


Pricing of Ag-RDTs has continued to decrease which will support self-testing at greater scale

- Continuous engagement with suppliers has enabled lower pricing, greater available capacity and shorter lead-times including through expanding the supplier base to include manufacturers with products approved by the stringent authorities in addition to the WHO EUL.
- **This resulted in:**
 - Total monthly manufacturing capacity > 100 million tests (~ 80 m tests available from the lowest price supplier)
 - Lowest prices are less than US\$1 per test (which is substantively lower than the current highest price of US\$2.25)
 - Availability of longer shelf life of up to 24 months
 - Key suppliers following the downward trend of lower pricing
- **Average weighted pricing in US\$1-2 range achievable in H1 2022** with a combination of supply and demand interventions
- **A range of COVID-19 Ag self-tests** is being made available with the manufacturer lead time of 1 to 4 weeks and prices ranging from around US\$1.00 – US\$5.00 per test.

Ag-RDTs: Weighted average prices achieved (PPM)



Total # COVID-19 Dx Tests procured through PPM



Increasing engagement for central PSA oxygen plant solutions complementing consumable solutions

Oxygen equipment and consumables

- No supply issues anticipated; steady supply of all products
- Increased need to identify remaining PR demand gaps in order to plan and assure supply
- Improved procurement service solution being finalized to drive more responsive performance with better quality data driving decision making

PSA* oxygen plants

- 10 countries re-channeling to central procurement (~US\$18.0m, ~36 plants) with PSA plant POs placed, anticipated installations completed in Q3 2022. A further 3 countries exploring re-channeling (~US\$8.5m, ~17 plants)
- Technical assistance, provided through Project BOXER, supports equipment specification finalization across these 10 central procurement engaged countries and a further 9 local procurement countries
- Second wave of central procurement countries to be engaged being planned
- Incrementally, local procurement solutions being progressed, such as orders placed, pre-award reviews ongoing and imminent RFPs




Therapeutics Overview

Current Focus

- The Global Fund is in negotiations with Pfizer to secure access to **Paxlovid**™ for all LMIC's in 2022 ahead of generic supply (not expected before H1 2023)
- **Molnupiravir**: Initial supply of originator product will be from UNICEF through wambo. Aim to supply licensed generics in H2 2022 subject to WHO PQ/ERP approval
- In coordination with ACT-A partners and countries, we are monitoring access (volume and price) and deployment for additional COVID-19 therapeutics.

Country Readiness and Implementation

- Burgeoning number of WHO-recommended Tx, oral antivirals
- Reprogramming: Identify early adopter countries, i.e., country-level approval, plans for test and treat clinical care pathways for most at risk populations, and with appropriate pharmacovigilance. (Work in progress)
- Leverage UNITAID/Find support.
- CMLI: may link to pending decisions on upstream and downstream activity investments
- Supporting ACT-A/HSRC clinical care pathway development



IPC/PPE Update



C19RM launched in June 2020 with strong focus on PPE. C19RM upgraded and heightened emphasis on IPC/PPE investments via Fast-track

- At the start of the COVID-19 pandemic, insufficient scientific evidence and consensus on critical importance of core PPE hampered clarity and effectiveness of key messaging and advocacy.
- Global PPE production capacity and supply chain faced an unprecedented challenge from COVID-19 with increased global demand especially in both HIC and LMIC during 2020.
- Through 2021, the supply/demand imbalance reduced with more available capacity and consequent lower pricing emerging – prices are 60% lower in 2022 vs, 2020:
 - High product availability despite manufacturing capacity reductions due to decreasing global demand 2021 (including high-impact countries)
 - No price increase forecasted in Q2 2022
 - Energy price increases may begin to be reflected in PPE pricing going forward
- Countries used the WHO Essential Supplies Forecasting Tool to variable extent, effect and duration.

Most C19RM PPE/IPC investments fund health products (>90%).

- Most spend (~80%) concentrated in Core PPE incl. gloves, masks, gowns, respirators
- Balanced distribution between central & local procurement (60/40); greater skew within countries & interventions.
- Partner PPE co-financing data were available in Full requests, though often insufficient.

Distribution of non-health product spend (5%) commensurate with key IPC priorities.

- The majority of spend (>70%) funds **IPC infrastructure projects and HR staffing needs.**

Procurement challenges alongside implementation challenges.

- Significant variability across countries.
- M&O data suggest slow rate of PPE order initiation via PPM and other procurement channels with 36% approved funds reported as converted into orders*

* price reductions of 60% 2022 vs. 2020 impact on this meaning more can be procured with the same funds


Significant concentration in PPE / IPC spend at the country and regional level.

- Across both health product and non-health product spending, the **top-10 countries** by investment size compromise approximately **~70% of the total investment amount.**



6

Awards by Countries and Regions



Drill Down – C19RM Fast-track Requests Approved 1/2

The Global Fund has awarded US\$696 million to 44 applicants via Fast-track.

Applicants to Fast-track have requested in average 7.3% of their 2020-2022 allocation.

Final Submission to Notification Letter sent in 7.8 business days on average.

Country or Multicountry	Region	Fast-track Requested Amount (US\$)	Fast-track Approved Amount (US\$)	Fast-track Approved Amount (% of 2020-2022 Allocation)
Bangladesh	High Impact Asia	34,300,107	14,957,765	9.4%
Benin	Central Africa	8,180,868	8,180,868	7.9%
Bhutan	South East Asia	706,964	654,363	18.5%
Bolivia (Plurinational State)	Latin America and Caribbean	3,174,093	3,174,093	15.0%
Burundi	Southern and Eastern Africa	1,248,913	1,336,336	1.1%
Cambodia	High Impact Asia	7,931,530	7,931,530	8.3%
Chad	Central Africa	6,339,903	5,053,986	3.9%
Congo	Central Africa	3,006,616	2,711,367	4.5%
Congo (Democratic Republic)	High Impact Africa 1	48,059,755	23,217,173	3.6%
Eswatini	Southern and Eastern Africa	5,516,616	2,131,901	4.0%
Ethiopia	High Impact Africa 2	55,709,764	47,173,812	10.6%
Gambia	Western Africa	4,973,481	3,682,162	8.5%
Georgia	Eastern Europe and Central Asia	877,824	877,824	5.0%
Ghana	High Impact Africa 1	34,264,927	27,317,287	12.1%
India	High Impact Asia	75,000,000	75,000,000	15.0%
Indonesia	High Impact Asia	22,581,895	15,316,626	5.2%
Kenya	High Impact Africa 2	31,148,545	31,148,545	7.5%
Madagascar	Southern and Eastern Africa	6,832,072	6,806,346	7.7%
Malawi	Southern and Eastern Africa	29,914,582	29,441,661	5.7%
Mali	High Impact Africa 1	5,021,028	5,021,028	2.8%
Mongolia	South East Asia	667,217	667,217	5.0%
Morocco	Middle East and North Africa	1,314,868	1,314,868	7.5%
Total awarded (part 1 and 2)		841,581,140	695,536,054	7.3%

Drill Down – C19RM Fast-track Requests Approved 2/2

The Global Fund has awarded US\$696 million to 44 applicants via Fast-track.

Applicants to Fast-track have requested in average 7.3% of their 2020-2022 allocation.

Final Submission to Notification Letter sent in 7.8 business days on average.

Country or Multicountry	Region	Fast-track Requested Amount (US\$)	Fast-track Approved Amount (US\$)	Fast-track Approved Amount % of 2020-2022 Allocation
Mozambique	High Impact Africa 2	24,041,916	20,120,458	2.7%
Multicountry Southern Africa MOSASWA	High Impact Africa 2	292,072	254,235	4.2%
Nepal	South East Asia	5,098,263	5,098,263	9.9%
Nigeria	High Impact Africa 1	110,889,278	50,083,594	5.6%
Pakistan	High Impact Asia	-	53,916,665	19.4%
Papua New Guinea	South East Asia	5,838,485	5,784,985	7.4%
Philippines	High Impact Asia	69,310,955	26,160,074	17.7%
Rwanda	Southern and Eastern Africa	11,329,802	11,329,802	6.0%
Senegal	Western Africa	7,190,917	7,174,661	9.3%
Solomon Islands	South East Asia	416,703	337,278	3.7%
Somalia	Middle East and North Africa	5,274,140	4,819,732	5.7%
South Africa	High Impact Africa 2	24,996,592	24,996,592	4.7%
Sri Lanka	South East Asia	1,414,093	1,414,093	15.0%
Tanzania (United Republic)	High Impact Africa 2	39,837,553	39,837,553	6.8%
Thailand	High Impact Asia	7,697,115	6,809,760	8.2%
Timor-Leste	South East Asia	1,957,159	1,412,259	9.0%
Togo	Central Africa	7,093,513	7,069,515	6.5%
Tunisia	Middle East and North Africa	239,949	239,949	5.0%
Uganda	High Impact Africa 2	28,950,088	14,163,072	2.4%
Ukraine	Eastern Europe and Central Asia	5,973,913	5,973,913	5.0%
Zambia	High Impact Africa 2	59,840,417	58,296,194	18.5%
Zimbabwe	High Impact Africa 2	37,126,648	37,126,648	7.4%
Total awarded (part 1 and 2)		841,581,140	695,536,054	7.3%

**The US\$54 million of Fast-track award to Pakistan was reviewed based on their Full FR which was split into Fast-track to accelerate deployment of urgent COVID-19 health products and Full Funding award in order to respond to the evolving emergency at country and regional levels.*

Drill Down – C19RM Full Funding Requests Total Awarded 1/4

US\$2,674 million awarded to 124 applicants, including funding recommended for Board approval, for a portfolio average of 21% of 2020-2022 allocation (excluding previously-approved Fast-track applications). An Unfunded Demand of US\$1,043 million in demand pipeline registered from 73 applicants.

Country or Multicountry	Region	Fast-track Approved Amount (% of 2020-2022 allocation)	Full FR Base Allocation Requested Amount (US\$)	Full FR Above Base Allocation Requested Amount (US\$)	Full FR Total Requested Amount (US\$)	Full FR Total Awarded Amount (US\$)	Full FR Total Awarded Amount (% of 2020-2022 Allocation)	Unfunded Demand (US\$)
Afghanistan	South East Asia	0%	8,716,104	8,716,104	17,432,208	14,964,287	26%	3,259,738
Albania	Eastern Europe and Central Asia	0%	245,720	1,356,501	1,602,221	819,056	50%	277,317
Algeria	Middle East and North Africa	0%	346,539	809,413	1,155,952	1,156,234	50%	1,056,239
Angola	Southern and Eastern Africa	0%	12,390,052	9,380,391	21,770,443	20,650,086	25%	1,120,357
Armenia	Eastern Europe and Central Asia	0%	1,450,000	3,513,213	4,963,213	4,838,131	50%	0
Azerbaijan	Eastern Europe and Central Asia	0%	2,589,181	8,628,041	11,217,223	5,336,571	31%	2,219,404
Bangladesh	High Impact Asia	9%	16,160,934	17,821,222	33,982,156	40,636,527	26%	0
Belarus	Eastern Europe and Central Asia	0%	5,133,499	5,287,605	10,421,104	10,418,072	50%	0
Belize	Latin America and Caribbean	0%	449,849	442,764	892,613	720,814	24%	0
Benin	Central Africa	8%	18,044,629	0	18,044,629	17,856,591	17%	0
Bhutan	South East Asia	19%	22,152	552,375	574,527	1,589,787	45%	0
Bolivia (Plurinational State)	Latin America and Caribbean	15%	0	11,725,693	11,725,693	7,576,871	36%	0
Botswana	Southern and Eastern Africa	0%	3,077,191	5,451,917	8,529,108	5,128,652	25%	2,147,657
Burkina Faso	High Impact Africa 1	0%	33,335,778	33,335,778	66,671,556	53,355,922	24%	12,612,651
Burundi	Southern and Eastern Africa	1%	16,505,290	19,744,048	36,249,338	28,674,082	24%	8,327,287
Cabo Verde	Central Africa	0%	708,403	1,676,646	2,385,049	2,385,041	51%	937,517
Cambodia	High Impact Asia	8%	6,404,012	20,664,458	27,068,470	15,961,038	17%	10,733,457
Cameroon	Central Africa	0%	41,360,597	39,492,569	80,853,166	68,933,959	25%	4,390,795
Central African Republic	Central Africa	0%	24,093,002	21,837,640	45,930,641	40,304,560	30%	0
Chad	Central Africa	4%	14,366,576	18,743,077	33,109,653	33,787,138	26%	0
Colombia	Latin America and Caribbean	0%	2,899,234	7,236,348	10,135,582	9,728,233	50%	353,902
Comoros	Southern and Eastern Africa	0%	1,054,869	537,908	1,592,777	1,758,114	25%	551,481
Congo	Central Africa	5%	16,501,501	2,235,498	18,736,999	15,328,333	25%	2,235,498
Congo (Democratic Republic)	High Impact Africa 1	4%	110,554,302	71,815,057	182,369,359	138,016,774	21%	7,932,919
Costa Rica	Latin America and Caribbean	0%	315,065	3,019,151	3,334,216	2,200,662	100%	1,043,292
Côte d'Ivoire	High Impact Africa 1	0%	38,297,602	35,018,648	73,316,250	55,089,231	22%	9,720,104
Cuba	Latin America and Caribbean	0%	2,609,229	12,421,277	15,030,506	13,161,237	76%	0
Djibouti	Middle East and North Africa	0%	1,634,379	1,634,379	3,268,758	2,669,588	24%	0
Dominican Republic	Latin America and Caribbean	0%	2,399,376	2,289,435	4,688,811	3,998,960	25%	424,608
Ecuador	Latin America and Caribbean	0%	897,796	2,989,651	3,887,447	3,887,447	65%	0
Egypt	Middle East and North Africa	0%	790,563	6,229,657	7,020,220	2,635,208	50%	4,385,012
Grand total across pt 1 to 4		7%	1,554,635,673	2,590,837,528	4,145,473,201	2,673,741,542	21%	1,042,729,474

Drill Down – C19RM Full Funding Requests Total Awarded 2/4

US\$2,674 million awarded to 124 applicants, including funding recommended for Board approval, for a portfolio average of 21% of 2020-2022 allocation (excluding previously-approved Fast-track applications). An Unfunded Demand of US\$1,043 million in demand pipeline registered from 73 applicants.

Country or Multicountry	Region	Fast-track Approved Amount (% of 2020-2022 allocation)	Full FR Base Allocation Requested Amount (US\$)	Full FR Above Base Allocation Requested Amount (US\$)	Full FR Total Requested Amount (US\$)	Full FR Total Awarded Amount (US\$)	Full FR Total Awarded Amount (% of 2020-2022 Allocation)	Unfunded Demand (US\$)
El Salvador	Latin America and Caribbean	0%	2,888,531	2,888,531	5,777,062	4,807,242	25%	969,820
Eritrea	Middle East and North Africa	0%	6,692,913	6,691,941	13,384,854	8,678,154	19%	0
Eswatini	Southern and Eastern Africa	4%	11,046,594	7,919,500	18,966,094	13,494,034	25%	6,361,444
Ethiopia	High Impact Africa 2	11%	35,999,489	138,453,454	174,452,943	86,191,837	19%	88,361,519
Gabon	Central Africa	0%	454,482	1,053,838	1,508,320	1,757,862	58%	0
Gambia	Western Africa	9%	2,804,340	6,486,700	9,291,040	7,128,355	16%	668,621
Georgia	Eastern Europe and Central Asia	5%	2,633,437	4,540,704	7,174,141	5,266,142	30%	1,030,176
Ghana	High Impact Africa 1	12%	20,190,804	48,423,634	68,614,438	44,049,194	19%	21,545,319
Guatemala	Latin America and Caribbean	0%	5,215,065	6,640,906	11,855,971	10,381,526	30%	2,337,161
Guinea	Western Africa	0%	20,433,615	20,433,615	40,867,230	34,013,965	25%	6,541,974
Guinea-Bissau	Western Africa	0%	8,457,412	2,071,079	10,528,492	14,057,307	25%	0
Guyana	Latin America and Caribbean	0%	1,044,727	987,862	2,032,589	1,963,090	30%	0
Haiti	Latin America and Caribbean	0%	17,907,284	14,332,870	32,240,154	29,570,380	25%	0
Honduras	Latin America and Caribbean	0%	2,804,246	8,399,982	11,204,228	9,347,487	50%	1,856,759
India	High Impact Asia	15%	0	54,941,154	54,941,154	37,919,394	8%	0
Indonesia	High Impact Asia	5%	50,688,885	89,144,619	139,833,504	72,492,980	25%	5,456,433
Iran (Islamic Republic)	South East Asia	0%	1,840,387	4,084,801	5,925,188	5,774,447	51%	141,319
Jamaica	Latin America and Caribbean	0%	1,680,678	1,674,935	3,355,613	3,355,614	29%	0
Kazakhstan	Eastern Europe and Central Asia	0%	5,333,474	2,205,442	7,538,916	7,619,249	50%	0
Kenya	High Impact Africa 2	8%	31,147,981	89,144,619	120,292,600	71,123,060	17%	49,764,717
Kosovo	Eastern Europe and Central Asia	0%	491,383	491,380	982,763	818,969	25%	163,795
Kyrgyzstan	Eastern Europe and Central Asia	0%	3,965,459	5,525,724	9,491,183	6,609,097	25%	0
Lao (Peoples Democratic Republic)	South East Asia	0%	4,304,948	4,210,236	8,515,184	7,130,717	26%	1,397,584
Lesotho	Southern and Eastern Africa	0%	12,100,176	8,440,450	20,540,626	16,691,047	25%	0
Liberia	Western Africa	0%	15,556,762	11,656,762	27,213,524	19,442,350	25%	12,034,349
Madagascar	Southern and Eastern Africa	8%	6,491,540	28,395,736	34,887,276	15,356,366	17%	2,291,632
Malawi	Southern and Eastern Africa	6%	47,498,535	76,940,862	124,439,397	73,113,943	14%	45,088,790
Mali	High Impact Africa 1	3%	21,797,112	26,421,607	48,218,719	36,134,202	20%	0
Mauritania	Western Africa	0%	4,896,937	4,899,309	9,796,246	6,376,024	33%	1,031,520
Mauritius	Southern and Eastern Africa	0%	339,782	1,034,821	1,374,603	566,303	25%	808,300
Moldova	Eastern Europe and Central Asia	0%	2,730,634	5,653,758	8,384,392	5,134,941	26%	2,892,647
Grand total across pt 2 to 4		7%	1,554,635,673	2,590,837,528	4,145,473,201	2,673,741,542	21%	1,042,729,474

Drill Down – C19RM Full Funding Requests Total Awarded 3/4

US\$2,674 million awarded to 124 applicants, including funding recommended for Board approval, for a portfolio average of 21% of 2020-2022 allocation (excluding previously-approved Fast-track applications). An Unfunded Demand of US\$1,043 million in demand pipeline registered from 73 applicants.

Country or Multicountry	Region	Fast-track Approved Amount (% of 2020-2022 allocation)	Full FR Base Allocation Requested Amount (US\$)	Full FR Above Base Allocation Requested Amount (US\$)	Full FR Total Requested Amount (US\$)	Full FR Total Awarded Amount (US\$)	Full FR Total Awarded Amount (% of 2020-2022 Allocation)	Unfunded Demand (US\$)
Mongolia	South East Asia	5%	2,085,273	2,085,273	4,170,546	4,170,546	31%	0
Montenegro	Eastern Europe and Central Asia	0%	93,000	311,899	404,898	309,446	50%	95,451
Morocco	Middle East and North Africa	7%	2,643,796	8,642,751	11,286,547	9,616,487	55%	0
Mozambique	High Impact Africa 2	3%	107,085,555	101,032,937	208,118,492	80,458,236	11%	37,713,278
Multicountry Africa ECSA-HC	High Impact Africa 2	0%	600,000	1,229,550	1,829,550	1,819,230	45%	0
Multicountry Americas EMMIE	Latin America and Caribbean	0%	900,000	3,121,125	4,021,125	3,038,520	51%	982,605
Multicountry Americas ORAS-CONHU	Latin America and Caribbean	0%	596,382	597,644	1,194,026	600,000	15%	318,494
Multicountry Caribbean CARICOM-PANCAP	Latin America and Caribbean	0%	974,720	30,000	1,004,720	974,720	15%	0
Multicountry Caribbean MCC	Latin America and Caribbean	0%	911,874	171,365	1,083,239	911,874	25%	171,365
Multicountry Eastern Africa IGAD	High Impact Africa 2	0%	750,000	787,800	1,537,800	1,430,000	29%	107,800
Multicountry EECA PAS	Eastern Europe and Central Asia	0%	749,846	0	749,846	749,846	15%	0
Multicountry HIV EECA APH	Eastern Europe and Central Asia	0%	1,950,000	882,557	2,832,557	1,466,591	11%	0
Multicountry HIV Latin America ALEP	Latin America and Caribbean	0%	1,575,000	0	1,575,000	1,228,849	12%	0
Multicountry MENA Key Populations	Middle East and North Africa	0%	1,125,000	0	1,125,000	1,125,000	15%	0
Multicountry Middle East MER	Middle East and North Africa	0%	10,943,717	13,372,630	24,316,347	23,795,068	50%	0
Multicountry Southern Africa E8	High Impact Africa 2	0%	2,100,000	0	2,100,000	1,908,144	14%	0
Multicountry Southern Africa MOSASWA	High Impact Africa 2	4%	625,877	150,088	775,965	625,877	10%	150,088
Multicountry TB Asia TEAM	High Impact Asia	0%	1,124,906	1,208,446	2,333,352	1,875,000	25%	343,745
Multicountry TB LAC PIH	Latin America and Caribbean	0%	675,000	0	675,000	675,000	15%	0
Multicountry TB WC Africa NTP/SRL	Central Africa	0%	750,001	332,692	1,082,692	750,001	15%	332,692
Multicountry Western Pacific	South East Asia	0%	1,988,226	1,988,226	3,976,452	3,313,710	25%	648,303
Myanmar	High Impact Asia	0%	45,848,163	45,848,163	91,696,326	91,696,326	30%	0
Namibia	Southern and Eastern Africa	0%	7,101,579	5,807,472	12,909,051	11,220,747	30%	0
Nepal	South East Asia	10%	2,647,604	21,317,623	23,965,227	23,919,800	46%	22,369
Nicaragua	Latin America and Caribbean	0%	3,297,183	3,297,183	6,594,366	5,491,838	25%	1,102,528
Niger	Western Africa	0%	20,543,578	11,773,020	32,316,598	27,391,437	20%	8,623,379
Nigeria	High Impact Africa 1	6%	83,789,554	137,964,367	221,753,921	172,565,824	19%	88,928,456
Pakistan	High Impact Asia	19%	63,889,858	43,391,287	107,281,145	28,142,218	10%	0
Panama	Latin America and Caribbean	0%	402,884	402,815	805,699	822,414	31%	0
Papua New Guinea	South East Asia	7%	5,937,093	12,187,078	18,124,171	17,159,866	22%	0
Paraguay	Latin America and Caribbean	0%	1,007,910	2,824,599	3,832,509	3,361,201	50%	471,309
Peru	Latin America and Caribbean	0%	2,987,577	9,271,463	12,259,040	14,937,883	75%	0
Grand total across pt 3 to 4		7%	1,554,635,673	2,590,837,528	4,145,473,201	2,673,741,542	21%	1,042,729,474

Drill Down – C19RM Full Funding Requests Total Awarded 4/4

US\$2,674 million awarded to 124 applicants, including funding recommended for Board approval, for a portfolio average of 21% of 2020-2022 allocation (excluding previously-approved Fast-track applications). An Unfunded Demand of US\$1,043 million in demand pipeline registered from 73 applicants.

Country or Multicountry	Region	Fast-track Approved Amount (% of 2020-2022 allocation)	Full FR Base Allocation Requested Amount (US\$)	Full FR Above Base Allocation Requested Amount (US\$)	Full FR Total Requested Amount (US\$)	Full FR Total Awarded Amount (US\$)	Full FR Total Awarded Amount (% of 2020-2022 Allocation)	Unfunded Demand (US\$)
Philippines	High Impact Asia	18%	3,699,809	72,430,732	76,130,541	18,983,858	13%	57,227,220
Romania	Eastern Europe and Central Asia	0%	681,958	1,227,146	1,909,104	1,637,748	36%	271,357
Russian Federation	Eastern Europe and Central Asia	0%	3,004,330	0	3,004,330	2,812,493	28%	0
Rwanda	Southern and Eastern Africa	6%	17,194,401	28,524,202	45,718,603	36,210,536	19%	7,995,201
Sao Tome and Principe	Central Africa	0%	1,935,130	1,934,824	3,869,954	3,869,954	30%	0
Senegal	Western Africa	9%	8,183,285	10,604,949	18,788,234	15,862,257	21%	2,975,244
Serbia	Eastern Europe and Central Asia	0%	248,166	567,256	815,423	808,804	49%	0
Sierra Leone	Western Africa	0%	18,930,753	18,864,409	37,795,162	31,551,255	25%	2,288,519
Solomon Islands	South East Asia	4%	1,060,463	1,397,742	2,458,205	1,507,621	16%	330,196
Somalia	Middle East and North Africa	6%	11,755,660	8,848,706	20,604,366	20,569,048	24%	0
South Africa	High Impact Africa 2	5%	80,514,995	80,514,994	161,029,989	161,029,989	30%	5,712,676
South Sudan	Middle East and North Africa	0%	20,346,596	18,279,889	38,626,485	30,386,833	25%	0
Sri Lanka	South East Asia	15%	3,965,459	6,056,639	10,022,098	1,532,064	16%	0
Sudan	Middle East and North Africa	0%	21,856,023	21,856,023	43,712,046	43,712,046	30%	0
Suriname	Latin America and Caribbean	0%	842,766	844,001	1,686,767	1,686,767	30%	0
Tajikistan	Eastern Europe and Central Asia	0%	3,767,608	4,552,232	8,319,840	6,279,003	25%	2,035,179
Tanzania (United Republic)	High Impact Africa 2	7%	48,253,026	149,797,429	198,050,455	73,078,995	12%	82,922,633
Thailand	High Impact Asia	8%	5,584,238	12,393,971	17,978,209	13,846,902	17%	2,824,486
Timor-Leste	South East Asia	9%	1,291,825	2,783,640	4,075,465	4,087,534	26%	532,832
Togo	Central Africa	6%	9,285,666	17,802,271	27,087,937	20,189,118	19%	6,230,202
Tunisia	Middle East and North Africa	5%	725,192	1,870,812	2,596,004	3,592,956	75%	5,541,000
Turkmenistan	Eastern Europe and Central Asia	0%	1,520,250	2,979,750	4,500,000	1,520,250	30%	3,007,750
Uganda	High Impact Africa 2	2%	86,850,290	377,933,717	464,784,007	141,649,508	24%	329,004,984
Ukraine	Eastern Europe and Central Asia	5%	17,699,115	23,793,624	41,492,739	35,843,480	30%	1,947,857
Uzbekistan	Eastern Europe and Central Asia	0%	6,617,957	6,701,861	13,319,818	10,928,120	25%	0
Venezuela	Latin America and Caribbean	0%	2,961,718	9,819,802	12,781,520	12,781,520	65%	0
Viet Nam	High Impact Asia	0%	21,892,237	23,045,859	44,938,096	34,631,047	24%	0
Zambia	High Impact Africa 2	18%	3,775,103	83,887,665	87,662,768	34,867,456	11%	31,523,650
Zanzibar	High Impact Africa 2	0%	1,682,497	2,721,808	4,404,305	2,804,162	25%	1,600,143
Zimbabwe	High Impact Africa 2	7%	38,016,965	109,974,227	147,991,192	87,996,041	18%	34,273,369
Grand total across pt 4 to 4		7%	1,554,635,673	2,590,837,528	4,145,473,201	2,673,741,542	21%	1,042,729,474

Drill Down – C19RM Full Funding Request Awarded by Priority Area 1/4

US\$2,674 million awarded Full Funding and Supplementary requests, including funding recommended for Board approval.

Full funding investments are still mainly directed towards reinforcing COVID-19 national response but present a more balanced picture across the priority areas than with Fast-track requests.

Country or Multicountry	Region	Mitigate COVID 19 impact on HIV, TB and malaria programs		Reinforce COVID 19 national response		Urgent improvement to health and community systems				Total Amount (US\$)
		Amount (US\$)	%	Amount (US\$)	%	Community, Gender and Rights		RSSH Investments		
						Amount (US\$)	%	Amount (US\$)	%	
Afghanistan	South East Asia	3,873,654	26%	10,509,222	70%	581,411	4%	0	0%	14,964,287
Albania	Eastern Europe and Central Asia	15,700	2%	787,006	96%	16,350	2%	0	0%	819,056
Algeria	Middle East and North Africa	12,431	1%	1,143,803	99%	0	0%	0	0%	1,156,234
Angola	Southern and Eastern Africa	2,173,149	11%	18,338,111	89%	56,941	0%	81,884	0%	20,650,086
Armenia	Eastern Europe and Central Asia	107,838	2%	3,725,381	77%	222,140	5%	782,772	16%	4,838,131
Azerbaijan	Eastern Europe and Central Asia	1,047,223	20%	3,156,843	59%	0	0%	1,132,506	21%	5,336,571
Bangladesh	High Impact Asia	11,401,319	28%	20,175,353	50%	2,261,098	6%	6,798,758	17%	40,636,527
Belarus	Eastern Europe and Central Asia	1,532,326	15%	8,230,537	79%	33,120	0%	622,089	6%	10,418,072
Belize	Latin America and Caribbean	14,900	2%	540,523	75%	132,670	18%	32,722	5%	720,814
Benin	Central Africa	202,034	1%	12,823,448	72%	257,119	1%	4,573,990	26%	17,856,591
Bhutan	South East Asia	392,343	25%	1,024,692	64%	0	0%	172,752	11%	1,589,787
Bolivia (Plurinational State)	Latin America and Caribbean	936,979	12%	5,418,843	72%	869,006	11%	352,044	5%	7,576,871
Botswana	Southern and Eastern Africa	619,481	12%	3,374,178	66%	596,036	12%	538,957	11%	5,128,652
Burkina Faso	High Impact Africa 1	7,366,020	14%	29,648,440	56%	4,401,289	8%	11,940,173	22%	53,355,922
Burundi	Southern and Eastern Africa	2,103,468	7%	24,206,784	84%	907,683	3%	1,456,146	5%	28,674,082
Cabo Verde	Central Africa	82,576	3%	2,229,257	93%	38,151	2%	35,057	1%	2,385,041
Cambodia	High Impact Asia	1,802,142	11%	13,530,743	85%	0	0%	628,152	4%	15,961,038
Cameroon	Central Africa	3,712,433	5%	55,192,971	80%	1,585,300	2%	8,443,256	12%	68,933,959
Central African Republic	Central Africa	2,045,525	5%	33,922,592	84%	906,664	2%	3,429,778	9%	40,304,560
Chad	Central Africa	2,836,826	8%	22,750,409	67%	2,505,259	7%	5,694,643	17%	33,787,138
Colombia	Latin America and Caribbean	363,645	4%	3,394,714	35%	1,338,042	14%	4,631,831	48%	9,728,233
Comoros	Southern and Eastern Africa	634,962	36%	1,089,497	62%	0	0%	33,655	2%	1,758,114
Congo	Central Africa	406,241	3%	9,944,267	65%	270,179	2%	4,707,645	31%	15,328,333
Congo (Democratic Republic)	High Impact Africa 1	19,246,197	14%	97,022,066	70%	2,703,333	2%	19,045,179	14%	138,016,774
Costa Rica	Latin America and Caribbean	546,241	25%	939,246	43%	715,174	32%	0	0%	2,200,662
Côte d'Ivoire	High Impact Africa 1	7,952,019	14%	39,607,578	72%	1,729,246	3%	5,800,387	11%	55,089,231
Cuba	Latin America and Caribbean	401,426	3%	12,280,906	93%	118,935	1%	359,971	3%	13,161,237
Djibouti	Middle East and North Africa	284,357	11%	1,862,158	70%	78,416	3%	444,656	17%	2,669,588
Dominican Republic	Latin America and Caribbean	112,091	3%	2,953,591	74%	181,955	5%	751,323	19%	3,998,960
Ecuador	Latin America and Caribbean	0	0%	2,270,743	58%	513,579	13%	1,103,019	28%	3,887,447
Egypt	Middle East and North Africa	743,153	28%	1,862,109	71%	29,946	1%	0	0%	2,635,208
Grand total across pt 1 to 4		364,881,711	14%	1,876,488,993	70%	129,374,211	5%	302,996,517	11%	2,673,741,542

Drill Down – C19RM Full FR Awarded by Priority Area 1/4

US\$2,674 million awarded Full Funding and Supplementary requests, including funding recommended for Board approval.

Full funding investments are still mainly directed towards reinforcing COVID-19 national response but present a more balanced picture across the priority areas than with Fast-track requests.

Country or Multicountry	Region	Mitigate COVID 19 impact on HIV, TB and malaria programs		Reinforce COVID 19 national response		Urgent improvement to health and community systems				Total
		Amount (US\$)	%	Amount (US\$)	%	Community, Gender and Rights		RSSH Investments		
						Amount (US\$)	%	Amount (US\$)	%	
El Salvador	Latin America and Caribbean	242,500	5%	2,533,708	53%	232,206	5%	1,798,828	37%	4,807,242
Eritrea	Middle East and North Africa	0	0%	8,104,615	93%	0	0%	573,539	7%	8,678,154
Eswatini	Southern and Eastern Africa	730,576	5%	11,468,709	85%	1,224,222	9%	70,527	1%	13,494,034
Ethiopia	High Impact Africa 2	5,095,086	6%	77,136,148	89%	2,548,016	3%	1,412,587	2%	86,191,837
Gabon	Central Africa	308,106	18%	1,050,400	60%	299,700	17%	99,657	6%	1,757,862
Gambia	Western Africa	463,897	7%	6,664,458	93%	0	0%	0	0%	7,128,355
Georgia	Eastern Europe and Central Asia	298,862	6%	4,222,544	80%	72,023	1%	672,712	13%	5,266,142
Ghana	High Impact Africa 1	11,822,312	27%	24,019,052	55%	3,378,700	8%	4,829,130	11%	44,049,194
Guatemala	Latin America and Caribbean	2,174,116	21%	7,619,736	73%	179,000	2%	408,674	4%	10,381,526
Guinea	Western Africa	5,085,494	15%	25,441,656	75%	1,808,348	5%	1,678,468	5%	34,013,965
Guinea-Bissau	Western Africa	371,489	3%	8,234,391	59%	1,437,202	10%	4,014,225	29%	14,057,307
Guyana	Latin America and Caribbean	302,727	15%	1,653,718	84%	6,645	0%	0	0%	1,963,090
Haiti	Latin America and Caribbean	4,508,015	15%	15,196,597	51%	4,577,616	15%	5,288,153	18%	29,570,380
Honduras	Latin America and Caribbean	60,006	1%	9,125,108	98%	106,679	1%	55,691	1%	9,347,487
India	High Impact Asia	14,771,083	39%	15,500,082	41%	7,486,906	20%	161,323	0%	37,919,394
Indonesia	High Impact Asia	26,297,671	36%	41,414,817	57%	3,367,223	5%	1,413,269	2%	72,492,980
Iran (Islamic Republic)	South East Asia	1,229,867	21%	2,046,816	35%	128,700	2%	2,369,065	41%	5,774,447
Jamaica	Latin America and Caribbean	1,768,527	53%	482,582	14%	515,397	15%	589,107	18%	3,355,614
Kazakhstan	Eastern Europe and Central Asia	1,581,863	21%	5,808,256	76%	0	0%	229,130	3%	7,619,249
Kenya	High Impact Africa 2	17,477,290	25%	43,029,452	61%	9,036,850	13%	1,579,468	2%	71,123,060
Kosovo	Eastern Europe and Central Asia	13,546	2%	764,829	93%	30,712	4%	9,881	1%	818,969
Kyrgyzstan	Eastern Europe and Central Asia	529,088	8%	4,697,970	71%	127,582	2%	1,254,457	19%	6,609,097
Lao (Peoples Democratic Republic)	South East Asia	1,601,382	22%	4,624,600	65%	883,901	12%	20,834	0%	7,130,717
Lesotho	Southern and Eastern Africa	2,896,420	17%	11,018,811	66%	1,131,129	7%	1,644,687	10%	16,691,047
Liberia	Western Africa	2,301,039	12%	16,097,000	83%	822,668	4%	221,642	1%	19,442,350
Madagascar	Southern and Eastern Africa	1,723,563	11%	11,321,622	74%	537,220	3%	1,773,961	12%	15,356,366
Malawi	Southern and Eastern Africa	12,245,244	17%	49,489,357	68%	7,374,580	10%	4,004,762	5%	73,113,943
Mali	High Impact Africa 1	4,697,726	13%	29,836,593	83%	517,206	1%	1,082,677	3%	36,134,202
Mauritania	Western Africa	228,192	4%	5,416,614	85%	122,337	2%	608,882	10%	6,376,024
Mauritius	Southern and Eastern Africa	69,737	12%	430,514	76%	0	0%	66,053	12%	566,303
Moldova	Eastern Europe and Central Asia	1,299,886	25%	2,319,031	45%	180,598	4%	1,335,425	26%	5,134,941
Grand total across pt 2 to 4		364,881,711	14%	1,876,488,993	70%	129,374,211	5%	302,996,517	11%	2,673,741,542

Drill Down – C19RM Full FR Awarded by Priority Area 1/4

US\$2,674 million awarded Full Funding and Supplementary requests, including funding recommended for Board approval.

Full funding investments are still mainly directed towards reinforcing COVID-19 national response but present a more balanced picture across the priority areas than with Fast-track requests.

Country or Multicountry	Region	Mitigate COVID 19 impact on HIV, TB and malaria programs		Reinforce COVID 19 national response		Urgent improvement to health and community systems				Total Amount (US\$)
		Amount (US\$)	%	Amount (US\$)	%	Community, Gender and Rights		RSSH Investments		
						Amount (US\$)	%	Amount (US\$)	%	
Mongolia	South East Asia	1,477,433	35%	2,508,678	60%	184,435	4%	0	0%	4,170,546
Montenegro	Eastern Europe and Central Asia	32,868	11%	258,379	83%	18,199	6%	0	0%	309,446
Morocco	Middle East and North Africa	807,642	8%	8,744,556	91%	64,288	1%	0	0%	9,616,487
Mozambique	High Impact Africa 2	13,838,096	17%	53,837,477	67%	4,947,231	6%	7,835,432	10%	80,458,236
Multicountry Africa ECSA-HC	High Impact Africa 2	0	0%	1,528,356	84%	0	0%	290,874	16%	1,819,230
Multicountry Americas EMMIE	Latin America and Caribbean	2,318,781	76%	401,349	13%	26,112	1%	292,277	10%	3,038,520
Multicountry Americas ORAS-CONHU	Latin America and Caribbean	371,039	62%	0	0%	43,261	7%	185,700	31%	600,000
Multicountry Caribbean CARICOM-PANCAP	Latin America and Caribbean	126,950	13%	497,560	51%	350,210	36%	0	0%	974,720
Multicountry Caribbean MCC	Latin America and Caribbean	0	0%	595,611	65%	26,500	3%	289,763	32%	911,874
Multicountry Eastern Africa IGAD	High Impact Africa 2	335,864	23%	1,094,136	77%	0	0%	0	0%	1,430,000
Multicountry EECA PAS	Eastern Europe and Central Asia	461,415	62%	288,431	38%	0	0%	0	0%	749,846
Multicountry HIV EECA APH	Eastern Europe and Central Asia	321,638	22%	697,077	48%	447,876	31%	0	0%	1,466,591
Multicountry HIV Latin America ALEP	Latin America and Caribbean	0	0%	309,130	25%	919,719	75%	0	0%	1,228,849
Multicountry MENA Key Populations	Middle East and North Africa	558,650	50%	403,202	36%	163,149	15%	0	0%	1,125,000
Multicountry Middle East MER	Middle East and North Africa	801,242	3%	21,271,690	89%	132,162	1%	1,589,974	7%	23,795,068
Multicountry Southern Africa E8	High Impact Africa 2	141,796	7%	1,063,918	56%	466,090	24%	236,340	12%	1,908,144
Multicountry Southern Africa MOSASWA	High Impact Africa 2	576,416	92%	49,462	8%	0	0%	0	0%	625,877
Multicountry TB Asia TEAM	High Impact Asia	704,716	38%	887,450	47%	244,566	13%	38,267	2%	1,875,000
Multicountry TB LAC PIH	Latin America and Caribbean	487,736	72%	166,891	25%	20,374	3%	0	0%	675,000
Multicountry TB WC Africa NTP/SRL	Central Africa	351,074	47%	398,927	53%	0	0%	0	0%	750,001
Multicountry Western Pacific	South East Asia	1,167,543	35%	1,464,234	44%	65,355	2%	616,578	19%	3,313,710
Myanmar	High Impact Asia	1,790,678	2%	85,472,010	93%	737,711	1%	3,695,927	4%	91,696,326
Namibia	Southern and Eastern Africa	3,509,094	31%	5,469,339	49%	774,023	7%	1,468,290	13%	11,220,747
Nepal	South East Asia	4,088,194	17%	16,028,571	67%	601,511	3%	3,201,524	13%	23,919,800
Nicaragua	Latin America and Caribbean	280,059	5%	4,571,063	83%	310,108	6%	330,608	6%	5,491,838
Niger	Western Africa	5,484,722	20%	20,188,391	74%	720,227	3%	998,097	4%	27,391,437
Nigeria	High Impact Africa 1	18,543,865	11%	118,237,901	69%	5,093,909	3%	30,690,148	18%	172,565,824
Pakistan	High Impact Asia	2,282,379	8%	17,726,661	63%	1,392,865	5%	6,740,313	24%	28,142,218
Panama	Latin America and Caribbean	321,000	39%	359,545	44%	99,445	12%	42,424	5%	822,414
Papua New Guinea	South East Asia	3,204,167	19%	7,803,276	45%	907,045	5%	5,245,378	31%	17,159,866
Paraguay	Latin America and Caribbean	630,841	19%	2,399,683	71%	158,236	5%	172,441	5%	3,361,201
Peru	Latin America and Caribbean	4,778,261	32%	8,454,225	57%	1,067,567	7%	637,831	4%	14,937,883
Grand total across pt 3 to 4		364,881,711	14%	1,876,488,993	70%	129,374,211	5%	302,996,517	11%	2,673,741,542

Drill Down – C19RM Full FR Awarded by Priority Area 1/4

US\$2,674 million awarded Full Funding and Supplementary requests, including funding recommended for Board approval.

Full funding investments are still mainly directed towards reinforcing COVID-19 national response but present a more balanced picture across the priority areas than with Fast-track requests.

Country or Multicountry	Region	Mitigate COVID 19 impact on HIV, TB and malaria programs		Reinforce COVID 19 national response		Urgent improvement to health and community systems				Total
						Community, Gender and Rights		RSSH Investments		
		Amount (US\$)	%	Amount (US\$)	%	Amount (US\$)	%	Amount (US\$)	%	
Philippines	High Impact Asia	12,511,010	66%	4,205,982	22%	469,170	2%	1,797,695	9%	18,983,858
Romania	Eastern Europe and Central Asia	287,218	18%	865,756	53%	0	0%	484,775	30%	1,637,748
Russian Federation	Eastern Europe and Central Asia	390,657	14%	1,546,462	55%	875,373	31%	0	0%	2,812,493
Rwanda	Southern and Eastern Africa	675,652	2%	31,289,041	86%	657,113	2%	3,588,729	10%	36,210,536
Sao Tome and Principe	Central Africa	165,933	4%	2,133,325	55%	453,004	12%	1,117,691	29%	3,869,954
Senegal	Western Africa	1,080,188	7%	13,305,659	84%	324,413	2%	1,151,996	7%	15,862,257
Serbia	Eastern Europe and Central Asia	363,646	45%	296,258	37%	148,900	18%	0	0%	808,804
Sierra Leone	Western Africa	1,803,512	6%	24,810,561	79%	3,026,374	10%	1,910,809	6%	31,551,255
Solomon Islands	South East Asia	110,335	7%	1,100,585	73%	80,227	5%	216,473	14%	1,507,621
Somalia	Middle East and North Africa	2,063,456	10%	8,519,092	41%	927,420	5%	9,059,080	44%	20,569,048
South Africa	High Impact Africa 2	16,993,036	11%	128,280,370	80%	3,504,616	2%	12,251,967	8%	161,029,989
South Sudan	Middle East and North Africa	554,692	2%	22,505,912	74%	2,688,634	9%	4,637,595	15%	30,386,833
Sri Lanka	South East Asia	75,882	5%	1,156,706	75%	0	0%	299,476	20%	1,532,064
Sudan	Middle East and North Africa	3,332,609	8%	31,078,162	71%	4,604,987	11%	4,696,287	11%	43,712,046
Suriname	Latin America and Caribbean	86,098	5%	1,518,392	90%	82,278	5%	0	0%	1,686,767
Tajikistan	Eastern Europe and Central Asia	120,995	2%	5,762,448	92%	374,194	6%	21,366	0%	6,279,003
Tanzania (United Republic)	High Impact Africa 2	5,609,116	8%	54,911,464	75%	3,421,919	5%	9,136,496	13%	73,078,995
Thailand	High Impact Asia	3,274,973	24%	7,679,011	55%	1,306,725	9%	1,586,194	11%	13,846,902
Timor-Leste	South East Asia	1,167,540	29%	2,339,309	57%	102,798	3%	477,886	12%	4,087,534
Togo	Central Africa	2,900,968	14%	15,135,701	75%	605,903	3%	1,546,546	8%	20,189,118
Tunisia	Middle East and North Africa	155,815	4%	3,096,373	86%	340,768	9%	0	0%	3,592,956
Turkmenistan	Eastern Europe and Central Asia	162,488	11%	1,246,040	82%	0	0%	111,723	7%	1,520,250
Uganda	High Impact Africa 2	10,584,560	7%	102,458,603	72%	5,327,156	4%	23,279,189	16%	141,649,508
Ukraine	Eastern Europe and Central Asia	12,413,279	35%	17,485,466	49%	4,146,496	12%	1,798,239	5%	35,843,480
Uzbekistan	Eastern Europe and Central Asia	2,408,101	22%	4,210,160	39%	513,000	5%	3,796,859	35%	10,928,120
Venezuela	Latin America and Caribbean	0	0%	12,462,678	98%	318,842	2%	0	0%	12,781,520
Viet Nam	High Impact Asia	5,605,146	16%	27,594,184	80%	507,190	1%	924,527	3%	34,631,047
Zambia	High Impact Africa 2	2,425,320	7%	27,423,921	79%	1,540,473	4%	3,477,742	10%	34,867,456
Zanzibar	High Impact Africa 2	267,506	10%	2,365,709	84%	43,333	2%	127,614	5%	2,804,162
Zimbabwe	High Impact Africa 2	12,333,809	14%	45,802,690	52%	1,818,323	2%	28,041,220	32%	87,996,041
		364,881,711	14%	1,876,488,993	70%	129,374,211	5%	302,996,517	11%	2,673,741,542

Mapping of C19RM Interventions to WHO, Global Fund Board categories and ACT-A

Refer to slides 13 – 17.

Intervention name	WHO categories	Board Category	Mapping to ACT-A (level 1)
Country-level coordination and planning	Pillar 1: Country-level coordination, planning, and monitoring	COVID-19 control and containment	Health Systems Connector
Risk communication	Pillar 2: Risk communication and community engagement	COVID-19 control and containment	Health Systems Connector
Surveillance- Epidemiological investigation and contact tracing	Pillar 3: Surveillance, rapid response teams, and case investigation	COVID-19 control and containment	Diagnostics Pillar
Surveillance systems	Pillar 3: Surveillance, rapid response teams, and case investigation	Health and community systems	Health Systems Connector
COVID Diagnostics and testing	Pillar 5: National laboratories	COVID-19 control and containment	Diagnostics Pillar
Laboratory systems	Pillar 5: National laboratories	Health and community systems	Health Systems Connector
Infection prevention and control and protection of the health workforce	Pillar 6: Infection prevention and control	COVID-19 control and containment	Health Systems Connector
Health products and waste management systems	Pillar 6: Infection prevention and control	Health and community systems	Health Systems Connector
Case management, clinical operations and therapeutics	Pillar 7: Case management	COVID-19 control and containment	Therapeutics Pillar
Mitigation for HIV programs	Pillar 9: Maintaining essential health services and systems	Mitigation for disease programs	Complementary ACT-A Activities
Mitigation for TB programs	Pillar 9: Maintaining essential health services and systems	Mitigation for disease programs	Complementary ACT-A Activities
Mitigation for Malaria programs	Pillar 9: Maintaining essential health services and systems	Mitigation for disease programs	Complementary ACT-A Activities
Gender-based violence prevention and post violence care	Community Rights and Gender	Health and community systems	Complementary ACT-A Activities
Respond to human rights and gender related barriers to services	Community Rights and Gender	Health and community systems	Complementary ACT-A Activities
COVID-19 CSS: Community-led monitoring	Community Rights and Gender	Health and community systems	Health Systems Connector
COVID-19 CSS: Community-led advocacy and research	Community Rights and Gender	Health and community systems	Health Systems Connector
COVID-19 CSS: Social mobilization	Community Rights and Gender	Health and community systems	Health Systems Connector
COVID-19 CSS: Community-based organizations institutional capacity building	Community Rights and Gender	Health and community systems	Health Systems Connector

Note that Global Fund Core Health Product costs are defined more strictly than in a given intervention. For example, PPE health product costs exclude disinfectants and other similar costs while WHO Pillar 6 includes these costs.